Guidance: Potency Assessment of Active Immunotherapy Products
FDA issued a guidance document on potency assessment for active immunotherapy products, providing recommendations for manufacturers to ensure product quality and consistency.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 19, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Manufacturers of active immunotherapy products, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that produce such products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline provided; guidance is effective immediately but compliance is expected for future submissions and ongoing manufacturing.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA guidance outlining recommended approaches for potency assessment of active immunotherapy products, emphasizing the need for robust and validated potency assays to support product quality and lot release.
Who it affects
Manufacturers of active immunotherapy products, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that produce such products.
What you must do
Review the guidance and assess current potency testing methods against the recommendations; update assays and validation protocols as needed to align with FDA expectations.
Deadline
No specific deadline provided; guidance is effective immediately but compliance is expected for future submissions and ongoing manufacturing.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.